Patent: 6,194,176

Summary for Patent: 6,194,176

Title:	Recombinant expression of proteins from secretory cell lines
Abstract:	The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.
Inventor(s):	Newgard; Christopher B. (Dallas, TX), Halban; Philippe (Geneva, CH), Normington; Karl D. (Dallas, TX), Clark; Samuel A. (Rockwell, TX), Thigpen; Anice E. (Dallas, TX), Quaade; Christian (Dallas, TX), Kruse; Fred (Dallas, TX)
Assignee:	Board of Regents, The University of Texas System (Austin, TX) Betagene, Inc. (Dallas, TX)
Application Number:	08/785,271
Patent Claims:	see list of patent claims

Details for Patent 6,194,176

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2016-01-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2016-01-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2016-01-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2016-01-19
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2016-01-19
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2016-01-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-01-19